Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Henry Meds vs REMEVi

Henry Meds
Graded #48

Higher grade

vs+3.8
REMEVi
Graded #78

Lower grade

The verdict

Henry Meds takes it — 77.3/100 to 73.5/100.

Henry Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Henry's low monthly equivalents come with a full year paid upfront, so it is a poor fit for someone shopping for a short trial.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHenry Meds +15
72
57
Dose & formulationREMEVi +3
80
83
Clinical oversightREMEVi +6
80
86
Labs & monitoringHenry Meds +23
78
55
FulfillmentREMEVi +19
78
97
Contract termsHenry Meds +9
78
69
Henry Meds · left barREMEVi · right bar

The numbers

MetricHenry MedsREMEVi
WeighScore77.3/10073.5/100
GradeC+C
Scorecard rank#48#78
Semaglutide$197/mo (injectable; 12-month plan paid upfront in full, $2,364)$219/mo
Tirzepatide$234/mo (compounded oral tablets; 12-month plan paid upfront in full, $2,808)$319/mo
CoverageMulti-stateAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
Henry Meds

Graded #48 · C+

Strengths

  • Published plan prices identify their upfront-payment requirement
  • Medication, provider access, applicable supplies and shipping included if prescribed
  • Compounded injectable semaglutide and oral options listed

Where it loses points

  • The $197 semaglutide headline requires $2,364 upfront, not monthly payments
  • The listed $234 tirzepatide offer is oral compounded medication, not an injectable quote
  • Multi-month balances may remain payable after cancellation; medical-discontinuation refunds require documentation and approval, and dispensed medication is excluded
REMEVi

Graded #78 · C

Strengths

  • A genuinely flat rate: 'the same price at every dose', stated as such, with no dose upcharge and no introductory rate to step off
  • Longer terms are published openly rather than used as a teaser — semaglutide falls to $189 on 12 weeks and $149 on 52
  • A daily oral semaglutide tablet is offered alongside the injection
  • Available in all 50 states and DC, with no minimum commitment and no cancellation fee

Where it loses points

  • The flat rate is the highest entry price of the top-scoring programs here; the cheaper $149 figure needs a full year
  • No FDA-approved brand-name pathway — the Wegovy and Ozempic pages are comparison content, not products
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products

Also worth a look

Another provider to compare: CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). CoreAge Rx advertises flat dose pricing for compounded injections, with no membership fee; its consultation-fee and refund deadlines deserve a close read before paying.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard